Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

Bleeding Clinical Trial

— WAS  

Official title:

Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00909363
• Other study ID #: 0801009600
• Status: Terminated
• Phase: Phase 2
• Start date: June 2009
• Est. completion date: June 30, 2017

Study information

• Verified date: March 2019
• Source: Weill Medical College of Cornell University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.

Description:

Wiskott Aldrich Syndrome is an X-linked disease characterized by immunodeficiency, eczema and thrombocytopenia; a milder form of the disease known as X-Linked thrombocytopenia also exists. The thrombocytopenia in both WAS and XLT is characterized by: severe thrombocytopenia with platelet counts frequently less than 10-30,000/ul; small platelets which may be dysfunctional; and, as a result, a high rate of serious bleeding including intracranial hemorrhage.

Because eltrombopag has been shown to be remarkably efficacious in substantially increasing platelet counts in a high percentage of ITP patients, this study seeks to effectively treat patients who exhibit similar pathologies, as well as evaluate the state of platelets in patients with WAS and relate it to clinical bleeding. It also aims to demonstrate whether eltrombopag administered daily will enhance stem cell function, increase platelet production and platelet count, and reduce bleeding in patients with WAS.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 24
• Est. completion date: June 30, 2017
• Est. primary completion date: May 15, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 3 Months to 80 Years

Eligibility

Inclusion Criteria:

In order to be eligible for study entry, subjects must comply with the following:

• Males from 3 months old to 80 years old

• Signed written informed consent obtained prior to study entry

• Clinical diagnosis of WAS or XLT

• Platelet levels less than 100 x 109/L

• Adequate renal and hepatic function (creatinine and bilirubin less than or equal to 1.5 x IULN, AST and ALT less than or equal to 2.5 x IULN)

Exclusion Criteria:

Any patient is ineligible for study entry if he/she:

• Over the age of 80

• Women (only males are eligible)

• fertile men who are not practicing or who are unwilling to practice birth control while enrolled in the study or until at least 6 months after treatment

• Aspirin, aspirin-containing compounds, salicylates, non-steroidal anti-inflammatory medications (NSAIDS), clopidogrel or ticlopidine, warfarin or other vitamin K antagonists, unfractionated or low molecular heparin within 7 days of first infusion

• Red blood cell transfusion in the past four weeks

• Elevated (> 1.5 x ULN) prothrombin time (PT) or partial thromboplastin time (PTT)

• New York Heart Classification III or IV heart disease. Other severe cardiovascular or cardiopulmonary disease, including COPD.

• Known HIV infection, hepatitis B or C infection

• Any infection requiring antibiotic treatment within 3 days

• Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.

• Prior malignancy with less than a 5-year disease-free interval, excluding nonmelanoma skin cancers and carcinoma in situ of the cervix

Related Conditions & MeSH terms

• Bleeding
• Hemorrhage
• Syndrome
• Thrombocytopenia
• Wiskott-Aldrich Syndrome

Intervention

Drug:
• Promacta
WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests. they will also have diagnostic blood testing prior to initiating treatment

Diagnostic Test:
• blood drawing in patients with WAS
blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
• blood drawing in healthy controls
blood will be drawn once in healthy children as controls for platelet parameters

Locations

Country	Name	City	State
United States	Weill Cornell Medical College	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University	Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	How Many WAS Patients Will Achieve Platelet Counts Above 50,000/ul.	number of WAS patients achieving this increase to > 50,000/uL without rescue medication in the previous 3 weeks during eltrombopag treatment	12 weeks
Secondary	Number of Patients With Wiskott-Aldrich Syndrome (WAS) With Grade 3 or Higher Bleeding or SAE (on WHO Scale)	number of patients with bleeding SAEs while on treatment and/or number of patients with grade 3 or higher bleeding on WHO (World Health Organization) scale: the scale is from 1 to 5 with 5 = fatality and 1=very little bleeding	12 Weeks
Secondary	How Many Patients With WAS Had Abnormal Platelet Function Including Activation	in how many patients with WAS were platelets dysfunctional or activated before treatment as measured by flow cytometry to a substantial degree and the same after treatment with eltrombopag	12 weeks
Secondary	How Many Patients With WAS Had Substantially Increased Platelet Production After Eltrombopag	in how many patients with WAS did eltrombopag increase platelet production as measured by the immature platelet fraction (IPF), a variable derived from the Sysmex auto analyzer, which is considered to be a measure of newly formed platelets ie reticulated platelets	12 weeks